Hypertension – Unmet Need – Detailed, Expanded Analysis 2020

Primary, or essential, hypertension is defined as persistently elevated blood pressure without any identifiable cause. It is a major risk factor for various cardiovascular diseases (e.g., coronary artery disease, stroke, heart failure), renal failure, and death. Hypertension is treated with a large array of drugs, and guidelines emphasize the additive effects of using two or more drugs from different antihypertensive drug classes. Despite numerous treatment options, significant unmet need remains for patients with resistant hypertension, in whom concurrent use of three or more antihypertensive agents does not adequately control blood pressure.


  • Which drug attributes most strongly influence antihypertensive drug selection?
  • How do cardiologists rate key current antihypertensive therapies across select drug attributes?
  • Where are the hidden opportunities for drug development in the hypertension therapy market?
  • Do U.S. and European cardiologists have different perceptions of the unmet need in the treatment of hypertension?


Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European cardiologists

Key drugs: ACE inhibitors, ARBs, diuretics, calcium-channel blockers, beta blockers, aldosterone antagonists

Table of contents

launch Related Market Assessment Reports